

**BRAWN**



713FC

CIN NO.: L74899DL1985PLC022468

29<sup>th</sup> May 2024

**The General Manager  
The Department of Corporate Services,  
BSE Limited, 25th Floor,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai -400001**

**BSE Scrip Code: 530207  
Scrip ID: BRAWN**

**Sub: Outcome of the Board Meeting of the Company held on 29<sup>th</sup> May 2024, and submissions of Audited Financial Results.**

**Ref: Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 (SEBI Listing regulations).**

Dear Sir/Ma'am,

With reference to the captioned subject and pursuant to the provisions of Regulation 30 and Regulation 33 of SEBI Listing Regulations, this is to inform you that the Board of Directors of the Company in its meeting held today, 29<sup>th</sup> May 2024 has considered and approved the Audited Standalone Financial Results for the quarter and financial year ended on March 31<sup>st</sup>, 2024.

A copy of the said results along with Auditor's Reports, issued by the Auditor is enclosed herewith.

The aforesaid Board Meeting Commenced at 12:30 P.M. (IST) and concluded at 01:00 P.M. (IST).

Kindly take the same on your record and acknowledge receipt of the same.

Thanking You.

**For and on behalf of  
Brawn Biotech Limited**

**Priyanka Sharma**  
**Company Secretary and Compliance Officer**  
**Membership No.: A50385**  
**Encl: As above**




**BRAWN BIOTECH LTD.**

(Formerly Known as Brawn Pharmaceuticals Ltd.)

Regd. Office : C-64, Lajpat Nagar-1, New Delhi-110024, INDIA Tel: 01129815331  
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Corporate Office : Plot No. - 30, Sector - 33, Near Hero Honda Factory, Gurugram - 122001, Haryana, INDIA Tel: 0124-4666152, 4222452  
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

*...for better life*



# BRAWN



BA796

CIN NO.: L74899DL1985PLC022468

BRAWN BIOTECH LIMITED CIN:L74899DL1985PLC022468 REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024						
STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31ST MARCH 2024						
Sr. No.	Particulars	Quarter Ended			Year Ended	
		31-Mar-24	31-Dec-23	31-Mar-23	31-Mar-24	31-Mar-23
		Un-audited	Un-audited	Un-audited	Audited	Audited
<b>1</b>	<b>Revenue from operations</b>					
	Revenue from operations	344.65	284.28	475.26	1,049.47	2,223.06
	Other Income	8.39	0.38	0.37	8.81	0.92
	<b>Total Revenue</b>	<b>353.04</b>	<b>284.66</b>	<b>475.63</b>	<b>1,658.27</b>	<b>2,223.99</b>
<b>2</b>	<b>Expenses</b>					
a	Cost of material consumed	-	-	(7.75)	-	-
b	Purchase of stock-in-trade	489.25	283.82	322.85	1,558.90	1,924.47
c	Change in inventories of finished goods, work in progress and stock in trade	(200.70)	(27.53)	76.88	(122.53)	(6.77)
d	Employee benefit expenses	32.11	35.77	38.21	140.01	139.92
e	Depreciation and amortisation expenses	2.77	2.71	3.54	9.94	10.91
f	Finance Cost	0.22	0.01	0.38	0.38	0.82
g	Other expenses	63.57	50.62	58.12	225.99	195.79
	<b>Total Expenses</b>	<b>387.22</b>	<b>345.40</b>	<b>492.22</b>	<b>1,812.70</b>	<b>2,265.14</b>
<b>3</b>	<b>Profit from Operation before Other Income, exceptional and extra-ordinary items (1-2)</b>	<b>(34.18)</b>	<b>(60.74)</b>	<b>(16.59)</b>	<b>(154.42)</b>	<b>(41.15)</b>
4	Other Income	-	-	-	-	-
5	<b>Profit from ordinary activities before exceptional items (3-4)</b>	<b>(34.18)</b>	<b>(60.74)</b>	<b>(16.59)</b>	<b>(154.42)</b>	<b>(41.15)</b>
6	Exceptional Items	-	-	-	-	-
7	<b>Profit from ordinary activities before tax (5-6)</b>	<b>(34.18)</b>	<b>(60.74)</b>	<b>(16.59)</b>	<b>(154.42)</b>	<b>(41.15)</b>
8	Tax Expenses	-	-	44.21	-	45.66
9	<b>Profit (Loss) for the period from continuing operations (7-8)</b>	<b>(34.18)</b>	<b>(60.74)</b>	<b>(60.80)</b>	<b>(154.42)</b>	<b>(86.81)</b>
10	Profit/(loss) from discontinuing operations	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-
12	<b>Profit/(loss) from Discontinuing operations (after tax) (10-11)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
13	<b>Profit (Loss) for the period (9+12)</b>	<b>(34.18)</b>	<b>(60.74)</b>	<b>(60.80)</b>	<b>(154.42)</b>	<b>(86.81)</b>
14	Other Comprehensive Income	0.70	0.17	(0.23)	0.28	(1.80)
	<b>Total Comprehensive Income</b>	<b>(33.48)</b>	<b>(60.57)</b>	<b>(61.03)</b>	<b>(154.14)</b>	<b>(91.11)</b>
15	Details of equity share capital					
	Paid-up equity share capital	300.03	300.03	300.03	300.03	300.03
	Face value of equity share capital					
16	Reserve excluding Revaluation Reserve					
17	Earnings per share					
i	Basic earnings per share	(1.12)	(2.02)	(2.03)	(5.14)	(3.04)
ii	Diluted earnings per share	(1.12)	(2.02)	(2.03)	(5.14)	(3.04)

**NOTES:-**

- Results for the quarter and year ended on 31st March, 2024 were reviewed by the Audit committee and then approved by the Board of Directors at their meeting held on 29th May, 2024.
- The Statutory Auditors carried out the audit for year ended 31st March, 2024. The management has exercised necessary due diligence to ensure that the financial results provided a true and fair view of its affairs.
- The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment rules), 2016 prescribed under Section 133 of the companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- The above Standalone audited Financial Results for the quarter and year ended ended on 31.03-2024 are available on company's website [www.brawnbiotech.com](http://www.brawnbiotech.com) and BSE website [www.bseindia.com](http://www.bseindia.com).
- Figures for the quarter ended 31st March 2024 are the differences between the figures for the year ended 31st March 2024 and Nine month ended 31st December 2023.
- Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board  
For Brawn Biotech Limited


*[Signature]*  
Brij Raj Gupta  
Director  
DIN NO. 00974969  
Date: 19-05-2024  
Place: Delhi

**BRAWN BIOTECH LTD.**  
(Formerly Known as Brawn Pharmaceuticals Ltd.)

Regd. Office : C-64, Lajpat Nagar-1, New Delhi-110024, INDIA Tel: 01129815331  
Email: [solution@brawnbiotech.com](mailto:solution@brawnbiotech.com), Website : [www.brawnbiotech.com](http://www.brawnbiotech.com)

Corporate Office : Plot No. - 30, Sector - 33, Near Hero Honda Factory, Gurugram - 122001, Haryana , INDIA Tel: 0124-4666152, 4222462  
Email: [solution@brawnbiotech.com](mailto:solution@brawnbiotech.com), Website : [www.brawnbiotech.com](http://www.brawnbiotech.com)

...for better life



# BRAWN

BRAWN BIOTECH LIMITED  
CIN:L74899DL1985PLC022468



B563E

CIN NO.: L74899DL1985PLC022468

REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024

Statement of Assets and Liabilities as on 31st March 2024		
Particulars	Rs. in Lacs	
	31-Mar-24 Audited	31-Mar-23 Audited
<b>ASSETS</b>		
<b>(1) Non-Current Assets</b>		
Property, Plant, Equipment & Intangible Assets	33.34	37.25
Financial Assets		
- Investment		
- Trade Receivable	65.93	59.94
- Loan		-
Deferred Tax Asset (Net)	45.66	15.94
<b>Total Non-Current Assets</b>	<b>144.92</b>	<b>113.12</b>
<b>(2) Current Assets</b>		
Inventories	601.66	479.13
Financial Assets		
- Trade Receivables	388.30	531.54
- Cash and cash equivalents	39.73	43.88
- Loan	2.04	1.62
- Other Financial Assets	112.65	112.65
Current Tax Assets (Net)		
Other Current Assets	169.57	171.11
<b>Total Current Assets</b>	<b>1,313.95</b>	<b>1,339.93</b>
<b>TOTAL ASSETS</b>	<b>1,458.88</b>	<b>1,453.05</b>
<b>EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
Equity Share Capital	300.03	300.03
Other Equity	206.47	330.90
<b>TOTAL EQUITY</b>	<b>506.50</b>	<b>630.93</b>
<b>LIABILITIES</b>		
<b>(1) Non-current Liabilities</b>		
Financial Liabilities		
- Trade Payable	289.88	7.79
- Other Financial Liabilities		
Provisions	11.73	9.67
Deferred Tax liabilities (Net)		
<b>Total Non-Current Liabilities</b>	<b>301.61</b>	<b>17.46</b>
<b>(2) Current Liabilities</b>		
Financial Liabilities		
- Trade Payables	567.49	646.90
- Other Financial Liabilities	38.08	42.44
Other current liabilities	37.14	107.79
Provisions	8.05	7.53
Current tax liabilities		
<b>Total Current Liabilities</b>	<b>650.76</b>	<b>804.66</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>1,458.88</b>	<b>1,453.05</b>

For and on behalf of Board  
For Brawn Biotech Limited

Brij Raj Gupta  
Director

**BRAWN BIOTECH LTD.**

Place: New Delhi, India (Formerly Known as Brawn Pharmaceuticals Ltd.)

Date: 29.05.2024

Regd. Office : C-64, Lajpat Nagar-1, New Delhi-110024, INDIA Tel: 01129815331  
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Corporate Office : Plot No. - 30, Sector - 33, Near Hero Honda Factory, Gurugram - 122001, Haryana , INDIA Tel: 0124-4666152, 4222462  
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

... for better life



# BRAWN



CIN NO.: L74899DL1985PLC022468

Brawn Biotech Limited

A4E4D

Cash Flow Statement for the year ended 31st March, 2024

CIN NO: L74899DL1985PLC022468

Rs. In Lacs

Particulars	For the year ended		For the year ended	
	31.03.2024		31.03.2023	
<b>A. Cash flow from operating activities</b>				
Net Profit / (Loss) before extraordinary items and tax		(154.42)		(41.15)
<b>Adjustments for:</b>				
Profit of sale of Investment (Shares)				
Depreciation and amortisation	5.12		10.91	
Re-measurement losses on defined benefit plans	0.28		(4.30)	
Finance costs	0.38	5.77	0.82	7.43
Operating profit / (loss) before working capital changes		(148.65)		(33.72)
<b>Changes in working capital:</b>				
<b>Adjustments for (increase) / decrease in operating assets:</b>				
Inventories	(122.53)		(6.77)	
Trade receivables	143.23		(250.56)	
Long Term - Trade receivables	(5.99)		(1.14)	
Short-term loans and advances	1.116521		157.48	
Long-term loans and advances				
<b>Adjustments for increase / (decrease) in operating liabilities:</b>				
Trade payables	(79.41)		241.71	
Long Term - Trade payables	282.08		(8.95)	
Borrowings				
Other current liabilities	(70.65)		7.47	
Other financial liabilities	(4.36)		(5.90)	
Current tax liabilities			(69.67)	
Long-term provisions	2.06806		2.09	
Short-term provisions	0.5223	146.08	(1.04)	64.72
Cash flow from extraordinary items				
Cash generated from operations		(2.56)		31.00
Net income tax (paid) / refunds & Dividend				0.80
<b>Net cash flow from / (used in) operating activities (A)</b>		<b>(2.56)</b>		<b>31.80</b>
<b>B. Cash flow from investing activities</b>				
Capital expenditure on fixed assets, including capital advances	(1.21)		(9.56)	
Cash flow from extraordinary items				
<b>Net cash flow from / (used in) investing activities (B)</b>		<b>(1.21)</b>		<b>(9.56)</b>
<b>C. Cash flow from financing activities</b>				
Proceeds from long-term borrowings				
Proceeds from other short-term borrowings				
Finance cost	(0.38)		(0.82)	
Cash flow from extraordinary items				
<b>Net cash flow from / (used in) financing activities (C)</b>		<b>(0.38)</b>		<b>(0.82)</b>
<b>Net increase / (decrease) in Cash and cash equivalents (A+B+C)</b>		<b>(4.15)</b>		<b>21.42</b>
Cash and cash equivalents at the beginning of the year		43.88		22.46
Effect of exchange differences on restatement of foreign currency Cash and cash equivalents				
<b>Cash and cash equivalents at the end of the year</b>		<b>39.73</b>		<b>43.88</b>
<b>Reconciliation of Cash and cash equivalents with the Balance Sheet:</b>				
Cash and cash equivalents as per Balance Sheet (Refer Note - 8)		39.73		43.88
Less: Bank balances not considered as Cash and cash equivalents				
<b>Net Cash and cash equivalents</b>		<b>39.73</b>		<b>43.88</b>
Add: Current investments considered as part of Cash and cash equivalents				
<b>Cash and cash equivalents at the end of the year *</b>		<b>39.73</b>		<b>43.88</b>
* Comprises:				
(a) Cash on hand		0.45		8.60
(b) Cheques, drafts on hand				
(c) Balances with banks				
(i) In current accounts		39.28		35.28

**Notes:**

- (i) The Cash Flow Statement reflects the combined cash flows pertaining to continuing and discounting operations,  
(ii) These earmarked account balances with banks can be utilised only for the specific identified purposes,  
Significant Accounting Policies & Notes on Financial Statements

For and on behalf of Board of Directors  
For Brawn Biotech Limited

Brij Raj Gupta

Director

DIN No. 01974265

**BRAWN BIOTECH LTD.**

(Formerly Known as Brawn Pharmaceuticals Ltd.)

Place: Delhi

Date: 29-03-2024

Corporate Office : C-64, Lajpat Nagar-1, New Delhi-110024, INDIA Tel: 01129815331  
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Corporate Office : Plot No. - 30, Sector - 33, Near Hero Honda Factory, Gurugram - 122001, Haryana, INDIA Tel: 0124-4666152, 4222462  
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

*... for better life*



**Independent Auditor's Report on Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To  
The Board of Directors of  
Brawn Biotech Limited

**Report on the audit of the Standalone Financial Results**

**Opinion**

We have audited the accompanying statement of quarterly and year to date standalone financial results of Brawn Biotech Limited (the "Company") for the quarter ended March 31, 2024 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. are presented in accordance with requirements of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2024 and for the year ended March 31, 2024.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Management's Responsibilities for the Standalone Financial Results**

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Act read with the relevant rules issued thereunder and other accounting principles.



generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

#### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional Skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to



events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Materiality is the magnitude of misstatements in the statement that, individually or in aggregate makes it probable that the economic decisions of a reasonably knowledgeable user of the statement may be influenced, We consider quantitative materiality and qualitative factors in (i) Planning the scope of our audit, work and in evaluating the results of our work; and (ii) to evaluate the effects of any identified misstatements in the statements
- We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
- We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### Other Matter

The Statement includes the results for the quarter ended March 31, 2024 being the balancing figures between the audited figures in respect of the full financial year ended March 31, 2024 and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us, as required under the Listing Regulations.

**For Rajiv Udai & Associates**  
**Chartered Accountants**  
**Firm Registration No. 18764N**



**Rajeev Jain**  
**(Partner)**

**Membership No.: 099767**  
**UDIN: 24099767BKBMUT9054**  
**Place: Delhi**  
**Date: 29-05-2024**

